UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): December 7, 2023

BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter)

Cayman Islands 001-37686 98-1209416
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 Cayman Islands (Address of Principal Executive Offices) (Zip Code)

Address of Principal Executive Offices) (Zip Code +1 (345) 949-4123

(Registrant's telephone number, including area code)
Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box	below if the Form 8-K filing	is intended to simulta	aneously satisfy the f	filing obligation of the	registrant under any	of the following
** *				0 0		C
provisions:						

☐ Written communication	ations pursuant to Rule 425 under the Securities Act (17 CFR 23)	0.425)
☐ Soliciting material	pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.1	4a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
American Depositary Shares, each representing 13			
Ordinary Shares, par value \$0.0001 per share	BGNE	The NASDAQ Global Select Market	
Ordinary Shares, par value \$0.0001 per share*	06160	The Stock Exchange of Hong Kong Limited	

^{*}Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR $\S 230.405$) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR $\S 240.12$ b-2). Emerging growth company \square

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 8.01. Other Events.

On December 7, 2023, BeiGene, Ltd. (the "Company") entered into a consulting agreement (the "2024 Consulting Agreement") with Dr. Xiaodong Wang, co-founder, director and Chairman of the Scientific Advisory Board, to renew the consulting arrangement between the Company and Dr. Wang on substantially the same terms and conditions as his existing consulting agreement, which will expire on December 31, 2023. Pursuant to the 2024 Consulting Agreement, Dr. Wang will continue to provide certain scientific and strategic advisory services to the Company as requested by the Company from time to time and will continue to receive an annual fixed consulting fee of \$100,000 for such services and such additional compensation, if any, that will be determined in the sole discretion of the Company, subject to compliance with the requirements of the applicable stock exchange listing rules. The 2024 Consulting Agreement will be effective from January 1, 2024 and will expire on December 31, 2026. The Company may terminate the 2024 Consulting Agreement upon 30 days' prior notice to Dr. Wang, provided that Dr. Wang will be entitled to payment for services performed prior to such date.

The foregoing description of the 2024 Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the 2024 Consulting Agreement, which the Company intends to file as an exhibit to a subsequent periodic report or on an amendment to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Exhibit Index

Exhibit No. Description

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BEIGENE, LTD.

Date: December 8, 2023 By: /s/ Chan Lee

Name: Chan Lee

Title: Senior Vice President, General Counsel